SC 13G/A | 2022-02-14 | Sessa Capital (Master), L.P. | XERIS PHARMACEUTICALS INC | 3,259,804 | 2.4% | EDGAR |
SC 13G | 2021-07-12 | BlackRock Inc. | XERIS PHARMACEUTICALS INC | 1,684,166 | 2.5% | EDGAR |
SC 13G | 2021-03-17 | Flynn James E | XERIS PHARMACEUTICALS INC | 5,526,709 | 5.0% | EDGAR |
SC 13G/A | 2021-02-16 | Redmile Group, LLC | XERIS PHARMACEUTICALS INC | 2,397,441 | 4.9% | EDGAR |
SC 13G/A | 2021-02-16 | ArrowMark Colorado Holdings LLC | XERIS PHARMACEUTICALS INC | 1,981,909 | 3.3% | EDGAR |
SC 13G/A | 2021-02-16 | Sessa Capital (Master), L.P. | XERIS PHARMACEUTICALS INC | 6,607,100 | 10.0% | EDGAR |
SC 13G/A | 2021-02-12 | Flynn James E | XERIS PHARMACEUTICALS INC | 2,614,379 | 5.0% | EDGAR |
SC 13G/A | 2021-02-11 | SOROS FUND MANAGEMENT LLC | XERIS PHARMACEUTICALS INC | - | 0.0% | EDGAR |
SC 13G/A | 2021-02-01 | BlackRock Inc. | XERIS PHARMACEUTICALS INC | 3,647,218 | 7.4% | EDGAR |
SC 13G | 2020-07-10 | SOROS FUND MANAGEMENT LLC | XERIS PHARMACEUTICALS INC | 2,487,581 | 5.3% | EDGAR |
SC 13G/A | 2020-03-10 | CITIGROUP INC | XERIS PHARMACEUTICALS INC | 506,033 | 1.4% | EDGAR |
SC 13G | 2020-02-21 | Sessa Capital (Master), L.P. | XERIS PHARMACEUTICALS INC | 2,481,283 | 6.9% | EDGAR |
SC 13G/A | 2020-02-14 | Redmile Group, LLC | XERIS PHARMACEUTICALS INC | 3,000,641 | 11.1% | EDGAR |
SC 13G | 2020-02-14 | ArrowMark Colorado Holdings LLC | XERIS PHARMACEUTICALS INC | 1,928,308 | 7.1% | EDGAR |
SC 13G/A | 2020-02-13 | Flynn James E | XERIS PHARMACEUTICALS INC | 1,084,625 | 4.0% | EDGAR |
SC 13G | 2020-02-07 | BlackRock Inc. | XERIS PHARMACEUTICALS INC | 2,196,747 | 8.1% | EDGAR |
SC 13G | 2020-02-07 | CITIGROUP INC | XERIS PHARMACEUTICALS INC | 2,201,839 | 8.2% | EDGAR |
SC 13G/A | 2020-01-10 | FMR LLC | XERIS PHARMACEUTICALS INC | 0 | 0.0% | EDGAR |
SC 13G/A | 2019-11-08 | Flynn James E | XERIS PHARMACEUTICALS INC | 921,975 | 3.4% | EDGAR |
SC 13G/A | 2019-02-13 | FMR LLC | XERIS PHARMACEUTICALS INC | 2,280,968 | 10.9% | EDGAR |